| Full Name | Jill Hall |
|---|---|
| Gender | Female |
| Speciality | Clinical Psychologist |
| Experience | 27 Years |
| Location | 111 3rd Ave, Atmore, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124173711 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC1900X | Psychologist - Counseling | 931 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southwest Alabama Behavioral Health Care Systems | 5395762835 | 3 |
News Archive
Heart attack patients who had previously undergone cardiac bypass surgery are about twice as likely to have a delay in receiving angioplasty, or another form of revascularization, compared to heart attack patients who had no history of bypass surgery or previous angioplasty.
ITG Isotope Technologies Garching GmbH (ITG), a specialist in the development and production of innovative radioisotopes, and Sydney-based, Australian Nuclear Science and Technology Organisation (ANSTO) have agreed on a broad, long-term collaboration on radioisotopes.
When combined with other treatments, the drug cetuximab-which works by slowing or stopping the growth of cancer cells-has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients-specifically those who carry a mutated form of a gene called KRAS-do not respond to the drug. Researchers at Fox Chase Cancer Center in Philadelphia, however, have been working on a way to overcome this resistance to cetuximab by unleashing a second cetuximab driven mechanism using a novel drug called ARI-4175.
The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults.
› Verified 3 days ago
| Entity Name | Southwest Alabama Behavioral Health Care Systems |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881628162 PECOS PAC ID: 5395762835 Enrollment ID: O20051025000128 |
News Archive
Heart attack patients who had previously undergone cardiac bypass surgery are about twice as likely to have a delay in receiving angioplasty, or another form of revascularization, compared to heart attack patients who had no history of bypass surgery or previous angioplasty.
ITG Isotope Technologies Garching GmbH (ITG), a specialist in the development and production of innovative radioisotopes, and Sydney-based, Australian Nuclear Science and Technology Organisation (ANSTO) have agreed on a broad, long-term collaboration on radioisotopes.
When combined with other treatments, the drug cetuximab-which works by slowing or stopping the growth of cancer cells-has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients-specifically those who carry a mutated form of a gene called KRAS-do not respond to the drug. Researchers at Fox Chase Cancer Center in Philadelphia, however, have been working on a way to overcome this resistance to cetuximab by unleashing a second cetuximab driven mechanism using a novel drug called ARI-4175.
The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults.
› Verified 3 days ago
| Entity Name | Southwest Alabama Behavioral Health Care Systems |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881628162 PECOS PAC ID: 5395762835 Enrollment ID: O20060111000468 |
News Archive
Heart attack patients who had previously undergone cardiac bypass surgery are about twice as likely to have a delay in receiving angioplasty, or another form of revascularization, compared to heart attack patients who had no history of bypass surgery or previous angioplasty.
ITG Isotope Technologies Garching GmbH (ITG), a specialist in the development and production of innovative radioisotopes, and Sydney-based, Australian Nuclear Science and Technology Organisation (ANSTO) have agreed on a broad, long-term collaboration on radioisotopes.
When combined with other treatments, the drug cetuximab-which works by slowing or stopping the growth of cancer cells-has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients-specifically those who carry a mutated form of a gene called KRAS-do not respond to the drug. Researchers at Fox Chase Cancer Center in Philadelphia, however, have been working on a way to overcome this resistance to cetuximab by unleashing a second cetuximab driven mechanism using a novel drug called ARI-4175.
The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jill Hall, PHD Po Box 1415, Atmore, AL 36504-1415 Ph: (251) 446-9894 | Jill Hall, PHD 111 3rd Ave, Atmore, AL 36502-2609 Ph: (251) 446-9894 |
News Archive
Heart attack patients who had previously undergone cardiac bypass surgery are about twice as likely to have a delay in receiving angioplasty, or another form of revascularization, compared to heart attack patients who had no history of bypass surgery or previous angioplasty.
ITG Isotope Technologies Garching GmbH (ITG), a specialist in the development and production of innovative radioisotopes, and Sydney-based, Australian Nuclear Science and Technology Organisation (ANSTO) have agreed on a broad, long-term collaboration on radioisotopes.
When combined with other treatments, the drug cetuximab-which works by slowing or stopping the growth of cancer cells-has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients-specifically those who carry a mutated form of a gene called KRAS-do not respond to the drug. Researchers at Fox Chase Cancer Center in Philadelphia, however, have been working on a way to overcome this resistance to cetuximab by unleashing a second cetuximab driven mechanism using a novel drug called ARI-4175.
The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults.
› Verified 3 days ago